ClinicalTrials.gg
CompletedNCT06557434Updated Nov 10, 2026

AV-23-001 AVAVA MIRIA Pilot Study

An interventional study of MIRIA in Wrinkle, Acne Scars - Mixed Atrophic and Hypertrophic and Pigmented Lesions, sponsored by AVAVA, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by AVAVA, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 4 months ago, and no results have been posted to the registry.
Updated Nov 10, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 47 studies in Hypertrophy with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Hypertrophy · United States.

Enrollment
34th of 41
10 · median 30
Started
2023
with 4 others
No phase
34 of 47
6 open now
Registered
40th of 47
by date
Lead sponsor
3 of 47
AVAVA, Inc.

Among the 47 studies in Hypertrophy with a site in United States, this one is the 34th largest by enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2023, is one of 34 with no phase, and was the 40th registered.

Hypertrophy

140 studies on the registry are indexed under Hypertrophy; 23 are open to participants now.

Browse Hypertrophy studies →

Open to participants now

8 of the 47 studies in Hypertrophy with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Hypertrophy studies recruiting now, 3 (23%) set no upper age limit and 7 (54%) stop at 75 or younger; none take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Hypertrophy with a site in United States, or all of them as a file.
02

Study summary

This non-significant risk study is intended to demonstrate the use of the MIRIA Skin Treatment System can show improvement in dermatologic conditions currently indicated for treatment with a laser (such as, but not limited to, benign pigmented lesions, benign cutaneous lesions, wrinkles, textural irregularities, or scars). The study is also intended to assist in determination of the optimal laser configuration and treatment parameters that most consistently yield results.

Read the detailed description

This study is intended to allow clinical evaluation of the feasibility of the MIRIA Skin Treatment System, referred to herein as the SR Skin Rejuvenation Laser, for the treatment of dermatologic conditions currently indicated for treatment with a laser (such as, but not limited to, benign pigmented lesions, benign cutaneous lesions, wrinkles, textural irregularities, or scars). This clinical evaluation is being performed under an investigational protocol to formally collect data for the treatment of different dermatologic conditions.

This prospective, non-randomized, controlled study will include subjects with dermatologic conditions that are currently indicated for treatment with a laser who are willing to have sites exposed to the MIRIA Laser and who agree to comply with the study requirements during the follow-up period, a minimum of 3 months and a maximum of 18 months. Some areas with the dermatologic condition may be left as a control for the treated section. Subjects may also be directed to use some topical cream or lotion for up to 1 month prior to the laser procedure or during the duration of the study, according to the Investigator's standard practice.

03

Conditions studied

  • Wrinkle
  • Acne Scars - Mixed Atrophic and Hypertrophic
  • Pigmented Lesions
  • Skin Laxity
  • Scars

Keywords

  • MIRIA
  • Laser
  • Wrinkles
  • Acne Scars
  • Skin Laxity
  • Skin Improvement
  • non-ablative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects > 18 years of age.
  2. Dermatologic condition currently indicated for laser treatment OR the subject is to be enrolled for assessment of treatment parameters on normal skin.
  3. Willingness to have multiple areas exposed.
  4. Willingness to have digital photographs taken of treatment area(s) and agreement with use of photographs for presentation, educational, or marketing purposes.
  5. Willingness to comply with the following during the study, including the follow-up period:

    1. maintain consistent skin care regimen on treated areas.
    2. Willingness to cover treated areas or have very limited sun exposure and, if requested, use an approved sunscreen of SPF 50 or higher.
    3. refrain from using systemic , according to Investigator discretion.
    4. refrain from using topical corticosteroids, retinoids, or prescription skin-lightening medications on the treated areas, according to Investigator discretion.
    5. refrain from any other procedures in the treatment areas.
  6. Willingness and ability to comply with study instructions and return for required visits.
  7. Subject understands that fees will be collected at the time of treatment ranging from $300 to $3000 per treatment depending upon number of anatomical areas treated. The exact amount will be disclosed and recorded within the consent.
  8. Subject has read and signed a written form.
  9. Subject lives within 50 miles of study site.
  10. For Males: Willingness to shave facial hair on treatment areas.

Exclusion criteria

Exclusion Criteria:

  1. Skin pathology or condition that could interfere with evaluation of the study procedure, e.g.,
  2. Systemic treatment prescribed within previous 6 months (e.g., oral medication such as isotretinoin)
  3. Surgical treatment in the target areas within previous 6 months (e.g., laser surgery)
  4. Active vitiligo, psoriasis, or eczema in the treatment area
  5. The timing of use of fillers, neuromodulators and other cosmetic procedures are at the discretion of the investigator.
  6. Topical treatment applied to target areas within the previous 1 month or according to Investigator discretion.
  7. Active suntan and unable or unlikely to refrain from tanning within the follow-up period.
  8. Artificial tanning in the target areas within the previous 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period.
  9. Active localized or systemic infection, or an open wound in area being treated.
  10. Lesions in the treatment areas suspicious for (skin cancer, melanoma)
  11. History of abnormal wound healing or abnormal scarring (e.g., hypertrophic or keloid)
  12. History of connective tissue disease, such as lupus or scleroderma.
  13. Any use of medication that is known to increase sensitivity to light according to Investigator's discretion (e.g., topicals that produce sensitivity to light may be used in areas other than the target area).
  14. History of gold therapy.
  15. History of disease stimulated by heat, such as recurrent herpes simplex or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.
  16. History of radiation to the treatment area or currently undergoing systemic chemotherapy for the treatment of cancer.
  17. For Female: Pregnancy or lactation, or intent to become pregnant within the study period.
  18. Significant uncontrolled concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.
  19. History of /immune deficiency disorder or currently using immunosuppressive medications.
  20. Current enrollment in a clinical study of any other unapproved drug or device unless it is a noninvasive dermal study for which the subject is in a follow-up period and has other areas of skin that meet the study criteria or has received an investigational drug or been treated with an investigational device within 30 days prior to entering this study.
  21. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Treated Cohort

    Experimental: Treatment with the MIRIA Laser 3-4 experimental treatments at 4-6 week intervals. Refine usage of device

    Device: MIRIA

Interventions

  • DeviceMIRIA

    The MIRIA Skin Treatment System is a 1550nm-based laser system indicated for use in dermatologic procedures requiring the coagulation of soft tissue, as well as for skin resurfacing procedures.

06

What researchers measure

Primary outcomes

  1. Global Aesthetic Improvement Scale (GAIS)

    Scale used to compare before and after images of subjects treated. Scores include the following: 1. \- Very Much Improved 2. \- Much Improved 3. \- Improved 4. \- No Change 5. \- Worse

    Time frame: 3 Months

Secondary outcomes

  1. Subject Questionnaire

    Questionnaire that evaluates the subjects impression of the treatment (overall discomfort score, satisfaction with treatment results, notes on treatment sensation).

    Time frame: Immediate Post Treatment, 3 Months Post Treatment

  2. Adverse Event Assessment

    An assessment of side effects and adverse event profile to ensure safety of treatment. Data collected included the event, the duration, the severity, and any other interventions that may occur due to the adverse event.

    Time frame: Immediate Post Treatment, 3 Months Post Treatment

07

Study locations

2 sites
  • Skinfluence Long Island
    Dix Hills, New York 11746, United States
  • Laser and Skin Surgery Center of New York
    New York, New York 10010, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jul 2024, 7 months.

Of 78 interventional studies with no phase under Hypertrophy, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 22. This study's 7 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2026 → Jul 2024 and completion Dec 2026 → Jul 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2023
First posted
Aug 16, 2024
StartActual
Nov 6, 2023
Primary completionActual
Jul 3, 2024was Dec 2026
CompletionActual
Jul 3, 2024was Dec 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 10, 2026
Primary completion
Dec 31, 2026→Jul 3, 2024 (actual)
Nov 10, 2026
Study completion
Dec 31, 2026→Jul 3, 2024 (actual)
Nov 10, 2026
Enrollment
200 (estimated)→10 (actual)
Nov 10, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionGlobal Aesthetic Improvement Scale (GAIS): how it is measured was reworded
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Active, not recruiting→Completed
    Primary completion Dec 31, 2026→Jul 3, 2024 (now actual)
    Study completion Dec 31, 2026→Jul 3, 2024 (now actual)
    Enrollment 200 (estimated)→10 (actual)
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionGlobal Aesthetic Improvement Scale (GAIS): how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06557434
Lead sponsor
AVAVA, Inc.
Responsible party
Sponsor
First posted
Aug 16, 2024
Start date
Nov 6, 2023
Primary completion
Jul 3, 2024
Completion
Jul 3, 2024
Last update
Nov 10, 2026

Study contacts

Hyemin Pomerantz, MD
principal investigator · AVAVA, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion